JP5513378B2 - 治療化合物 - Google Patents

治療化合物 Download PDF

Info

Publication number
JP5513378B2
JP5513378B2 JP2010512211A JP2010512211A JP5513378B2 JP 5513378 B2 JP5513378 B2 JP 5513378B2 JP 2010512211 A JP2010512211 A JP 2010512211A JP 2010512211 A JP2010512211 A JP 2010512211A JP 5513378 B2 JP5513378 B2 JP 5513378B2
Authority
JP
Japan
Prior art keywords
disorders
compound
independently
pharmaceutical composition
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010512211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529986A5 (enExample
JP2010529986A (ja
Inventor
ブース，レイモンド，ジー．
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド
Publication of JP2010529986A publication Critical patent/JP2010529986A/ja
Publication of JP2010529986A5 publication Critical patent/JP2010529986A5/ja
Application granted granted Critical
Publication of JP5513378B2 publication Critical patent/JP5513378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010512211A 2007-06-15 2008-06-13 治療化合物 Active JP5513378B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93474307P 2007-06-15 2007-06-15
US60/934,743 2007-06-15
US7038608P 2008-03-21 2008-03-21
US61/070,386 2008-03-21
PCT/US2008/007458 WO2008156707A1 (en) 2007-06-15 2008-06-13 Therapeutic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014066482A Division JP6063410B2 (ja) 2007-06-15 2014-03-27 治療化合物

Publications (3)

Publication Number Publication Date
JP2010529986A JP2010529986A (ja) 2010-09-02
JP2010529986A5 JP2010529986A5 (enExample) 2011-08-04
JP5513378B2 true JP5513378B2 (ja) 2014-06-04

Family

ID=40156534

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010512211A Active JP5513378B2 (ja) 2007-06-15 2008-06-13 治療化合物
JP2014066482A Expired - Fee Related JP6063410B2 (ja) 2007-06-15 2014-03-27 治療化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014066482A Expired - Fee Related JP6063410B2 (ja) 2007-06-15 2014-03-27 治療化合物

Country Status (4)

Country Link
US (2) US8586634B2 (enExample)
EP (1) EP2164324B1 (enExample)
JP (2) JP5513378B2 (enExample)
WO (1) WO2008156707A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905515D0 (en) * 2009-03-31 2009-05-13 Ge Healthcare Ltd Radiolabelling methods
WO2010129048A2 (en) * 2009-05-05 2010-11-11 University Of Florida Research Foundation, Inc. Therapeutic compounds
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
AU2011296015B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
SG10201506865WA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
UY34436A (es) 2012-10-09 2014-07-31 Arena Pharm Inc Metodo de control del peso
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3145906B1 (en) * 2014-05-19 2023-10-04 Northeastern University Serotonin receptor-targeting compounds
BR112017024745A2 (pt) 2015-05-19 2018-11-13 Univ Northeastern compostos e métodos para modulação de receptores de serotonina na periferia.
CN117730073A (zh) * 2021-07-14 2024-03-19 东北大学 血清素5-ht2a、5-ht2b和5-ht2c受体反向激动剂
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH427780A (de) 1962-08-30 1967-01-15 Sandoz Ag Verfahren zur Herstellung von neuen Aryl-tetralyl-Verbindungen
FR1480455A (fr) 1965-05-05 1967-05-12 Geigy Ag J R Méthano-benzazocines et leur préparation
FR2319332A1 (fr) * 1975-07-28 1977-02-25 Roussel Uclaf Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits
FR2353519A1 (fr) 1975-12-08 1977-12-30 Roussel Uclaf Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits
WO1987004430A2 (en) * 1986-01-16 1987-07-30 Schering Corporation Fused benzazepines
HUT58035A (en) 1988-07-29 1992-01-28 Schering Corp Process for enanthiospecific synthesis of intermediates of hexahydrobenzo(d)naphtno(2,1-b)azepines
JPH05217455A (ja) 1992-01-31 1993-08-27 Tanaka Kikinzoku Kogyo Kk 電気接点の製造方法
US5461147A (en) 1993-09-27 1995-10-24 Schering Corporation Process for preparing benzazepine intermediates for the synthesis of D1 antagonists
JP2002539774A (ja) * 1999-03-15 2002-11-26 メルク エンド カムパニー インコーポレーテッド マウスセロトニン５−ＨＴ２ｃレセプターのアイソフォーム
US6875866B2 (en) 2002-02-21 2005-04-05 Schering Corporation Process for synthesis of D1 receptor antagonists
WO2003072093A1 (en) * 2002-02-22 2003-09-04 The Regent Of The University Of California METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs)
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
JP2006526021A (ja) 2003-05-22 2006-11-16 シェーリング　コーポレイション 肥満およびｃｎｓ障害を治療する選択的ｄ１／ｄ５レセプタアンタゴニストとしての５ｈ−ベンゾ［ｄ］ナフト［２，１−ｂ］アゼピン誘導体
US7115767B2 (en) 2003-07-18 2006-10-03 Abbott Laboratories Tetraline derivatives as ghrelin receptor modulators
KR20060134041A (ko) * 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 음식물 섭취 관리 방법
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
KR101381768B1 (ko) 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제

Also Published As

Publication number Publication date
JP2014141514A (ja) 2014-08-07
US20140155490A1 (en) 2014-06-05
US9422229B2 (en) 2016-08-23
EP2164324B1 (en) 2014-08-13
JP6063410B2 (ja) 2017-01-18
US8586634B2 (en) 2013-11-19
WO2008156707A1 (en) 2008-12-24
US20100305212A1 (en) 2010-12-02
EP2164324A1 (en) 2010-03-24
JP2010529986A (ja) 2010-09-02
EP2164324A4 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
JP5513378B2 (ja) 治療化合物
US9862674B2 (en) Therapeutic compounds and methods of use
JP6328170B2 (ja) 治療化合物
WO2009061436A1 (en) Compound for activating 5-ht2c receptors in combination with an amphetamine compound
US8765816B2 (en) Inhibitors of cognitive decline
TW589183B (en) A combination of a 5-HT reuptake inhibitor and a h5-HT1B antagonist or partial agonist
TWI226829B (en) Pharmaceutical compositions for treatment of partial responders or refractory depression
US9815770B2 (en) Inhibitors of cognitive decline
US20090186916A1 (en) Aminoindane derivative or salt thereof
Morgan et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications
US5958429A (en) Potentiation of serotonin response
WO1997006792A1 (en) Potentiation of serotonin response
TWI359661B (en) Carbostyril derivatives and serotonin reuptake inh
JP2014511373A (ja) ウコン油から単離された化合物およびその使用方法
Uth et al. Synthesis and biological evaluation of natural-product-inspired, aminoalkyl-substituted 1-benzopyrans as novel antiplasmodial agents
CN103635190B (zh) 治疗方案
US5298509A (en) Octahydronaphthoquinolizines, and methods of making and using thereof
McGlynn et al. Development of 2-Aminotetralin-Type Serotonin 5-HT1 Agonists: Molecular Determinants for Selective Binding and Signaling at 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT1F Receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140327

R150 Certificate of patent or registration of utility model

Ref document number: 5513378

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250